Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer
Public ClinicalTrials.gov record NCT02397083. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Study of the Levonorgestrel Intrauterine Device Alone or in Combination With the mTORC1 Inhibitor, Everolimus, for the Treatment of Complex Atypical Hyperplasia and Stage Ia Grade 1 Endometrial Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This randomized phase II trial studies how well levonorgestrel-releasing intrauterine system works when given alone or with everolimus in treating patients with atypical hyperplasia (a pre-cancerous growth of the lining of the uterus) or stage IA grade 1 endometrial cancer. The levonorgestrel-releasing intrauterine system is designed to prevent pregnancy by releasing a hormone called levonorgestrel, which is a type of progesterone. Progesterone is a common type of hormone that is used to prevent pregnancy and may prevent or slow tumor cell growth. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether the levonorgestrel-releasing intrauterine system works better with or without everolimus in treating patients with atypical hyperplasia or stage IA grade 1 endometrial cancer.
Study identification
- NCT ID
- NCT02397083
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 102 participants
Conditions and interventions
Conditions
Interventions
- Everolimus Drug
- Laboratory Biomarker Analysis Other
- Levonorgestrel-Releasing Intrauterine System Device
Drug · Other · Device
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 23, 2015 (Actual)
- Primary completion
- Sep 30, 2028 (Estimated)
- Completion
- Sep 30, 2028 (Estimated)
- Last update posted
- Sep 10, 2026
2015 – 2028
United States locations
- U.S. sites
- 18
- U.S. states
- 9
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| North Colorado Medical Center | Greeley | Colorado | 80631 | — |
| McKee Medical Center | Loveland | Colorado | 80539 | — |
| Queen's Medical Center | Honolulu | Hawaii | 96813 | — |
| Covenant HealthCare Mackinaw | Saginaw | Michigan | 48604 | — |
| Cooper Hospital University Medical Center | Camden | New Jersey | 08103 | — |
| MD Anderson Cancer Center at Cooper-Voorhees | Voorhees Township | New Jersey | 08043 | — |
| Northwell Health | New Hyde Park | New York | 11042 | — |
| OhioHealth Mansfield Hospital | Mansfield | Ohio | 44903 | — |
| University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | 73104 | — |
| MD Anderson in The Woodlands | Conroe | Texas | 77384 | — |
| Memorial Hermann Memorial City Medical Center | Houston | Texas | 77024 | — |
| Lyndon Baines Johnson General Hospital | Houston | Texas | 77026-1967 | — |
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
| The Woman's Hospital of Texas | Houston | Texas | 77054 | — |
| MD Anderson West Houston | Houston | Texas | 77079 | — |
| MD Anderson League City | League City | Texas | 77573 | — |
| MD Anderson in Sugar Land | Sugar Land | Texas | 77478 | — |
| University of Virginia Cancer Center | Charlottesville | Virginia | 22908 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02397083, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 10, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02397083 live on ClinicalTrials.gov.